|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 5/22/06 Viropharma Inc 8-K:7,9 5/21/06 2:56K RR Donnelley/FA |
Document/Exhibit Description Pages Size 1: 8-K Viropharma Incorporated--Form 8-K HTML 15K 2: EX-99.1 Press Release HTML 17K
| ViroPharma Incorporated--Form 8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 21, 2006
VIROPHARMA INCORPORATED
(Exact Name of Registrant as Specified in its Charter)
| DELAWARE | 0-021699 | 23-2789550 | ||
| (State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
397 EAGLEVIEW BOULEVARD, EXTON, PENNSYLVANIA 19341
(Address of Principal Executive Offices including Zip Code)
(610) 458-7300
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure
On May 21, 2006, ViroPharma Incorporated issued a press release announcing that data from a Phase 1b trial of HCV-796, an orally dosed non-nucleoside viral polymerase inhibitor with the potential to interfere with the replication of hepatitis C virus were presented at the 2006 Digestive Disease Week conference. A copy of the press release is set forth as Exhibit 99.1 attached hereto.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
| 99.1 | Press Release dated May 21, 2006 regarding data from a Phase 1b trial of HCV-796 presented at the 2006 Digestive Disease Week conference. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VIROPHARMA INCORPORATED | ||||
| Date: May 22, 2006 | By: | /s/ Thomas F. Doyle | ||
| Thomas F. Doyle | ||||
| Vice President, General Counsel and Secretary | ||||
| Exhibit No. | Description | |
| EX-99.1 | Press Release dated May 21, 2006 regarding data from a Phase 1b trial of HCV-796 presented at the 2006 Digestive Disease Week conference. |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/22/06 | 8-K | ||
| For Period End: | 5/21/06 | |||
| List all Filings | ||||